Biogen vs Neurocrine Biosciences
BIIB and NBIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BIIB and NBIX compare
Biogen is the larger company, worth 2.5 times as much as Neurocrine Biosciences ($37.5B against $14.9B).
On earnings, Neurocrine Biosciences is cheaper: it trades at 21.4× trailing earnings, against 44.9× for Biogen.
Neurocrine Biosciences grew revenue faster over the last twelve months (34.4% versus 0.31% for Biogen).
Neurocrine Biosciences keeps more of each dollar of sales as profit, with a net margin of 20.9% compared with 8.3% at Biogen.
Neurocrine Biosciences scores higher on the StockData Score (19 against 4 for Biogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BIIB | NBIX |
|---|---|---|
| Size and price | ||
| Market cap | $37.5B | $14.9B |
| Share price | $253.62 | $146.10 |
| Change, 1 year | 71.5% | 5.9% |
| Change, 5 years | −9.0% | 56.7% |
| Beta (5Y) | 0.51 | 0.49 |
| Employees | 7,500 | 1,800 |
| StockData Score | ||
| Total score | 4 | 19 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 5 (better) |
| Performance score | 1 | 5 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 44.9× | 21.4× (better) |
| P/S | 3.7× (better) | 4.4× |
| P/B | – | 4.0× |
| EV/EBITDA | 16.9× (better) | 18.2× |
| P/FCF | 13.9× (better) | 17.1× |
| PEG | – | 0.49 |
| FCF yield | 7.2% (better) | 5.9% |
| Fair value | $157.62 | $177.51 |
| Margin of safety | −60.9% | 17.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 0.31% | 34.4% (better) |
| Revenue growth, 5Y average | −6.0% | 22.3% (better) |
| Net income growth (TTM) | −45.5% | 103% (better) |
| EPS growth (TTM) | −46.0% | 102% (better) |
| EPS growth, 5Y average | −18.7% | 2.3% (better) |
| Profitability | ||
| Gross margin | 74.0% | 98.0% (better) |
| Operating margin | – | 23.6% |
| Net margin | 8.3% | 20.9% (better) |
| FCF margin | 26.9% (better) | 25.8% |
| Return on equity | – | 22.1% |
| Return on invested capital | – | 23.7% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 1.87 | 1.87 (better) |
| Altman Z-score | 3.05 | 6.83 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.84% |
| Shareholder yield | 0.00% (better) | −0.84% |
| Ownership | ||
| Held by institutions | 96.3% | 99.5% |
| Held by insiders | 0.21% | 1.2% |
| Insider net buying, 12 months | −$905K (better) | −$77.9M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 4.0% | 5.8% |
Go deeper
- BIIB stock overview
- BIIB income statement
- BIIB valuation and score
- NBIX stock overview
- NBIX income statement
- NBIX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.